Nuke, I think you misunderstand my post. Kiwi is criticizing our current management for not running more clinical trials. I am actually defending both current and past management. I think it would be a waste of money to run any more trials to prove the value of icosapent ethyl for cardiovascular risk reduction. Do you disagree? You made your decision about who you think should be running the company, and your not whining about what they are doing. I have no problem with what I have seen current management do to date. Sleven,
Market Data 
Markets 
AI
